ev3 Expands Neurovascular Division With Acquisition Of Chestnut
This article was originally published in The Gray Sheet
Executive Summary
ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2
You may also be interested in...
Covidien’s Pipeline, NovoCure’s NovoTFF Set For FDA Panel Review
FDA’s Neurological Devices panel is set to review Covidien’s Pipeline embolization device and NovoCure’s NovoTFF-100A brain tumor treatment kit during a March 17-18 meeting.
Covidien’s Pipeline, NovoCure’s NovoTFF Set For FDA Panel Review
FDA’s Neurological Devices panel is set to review Covidien’s Pipeline embolization device and NovoCure’s NovoTFF-100A brain tumor treatment kit during a March 17-18 meeting.
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.